 |
23 Diseases |  |
0 Trials |
|
0 Trials |  |
26 News |  |
- Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo (Section 52) - Mar 5, 2024 - Abstract #AACR2024AACR_3471;
Abstract is embargoed at this time.
- upifitamab rilsodotin (XMT-1536) / Mersana, lifastuzumab vedotin (DNIB0600A) / Roche
NaPi2b-ADC biological rationale and clinical development of upifitamab rilsodotin (UpRi, XMT- 1536) and lifastuzumab vedotin (LIFA) (South Hall 1) - Oct 18, 2021 - Abstract #ESGO2021ESGO_1125;
Abstract is embargoed at this time. Sponsored by Mersana Therapeutics
- upifitamab rilsodotin (XMT-1536) / Mersana, lifastuzumab vedotin (DNIB0600A) / Roche
[VIRTUAL] NaPi2b-ADC biological rationale and clinical development of upifitamab rilsodotin (UpRi, XMT- 1536) and lifastuzumab vedotin (LIFA) (Industry Hall 2) - Jul 29, 2021 - Abstract #IGCS2021IGCS_377;
Sponsored by Mersana Therapeutics Supported by Mersana Therapeutics
- || lifastuzumab vedotin (DNIB0600A) / Roche
Biomarker, Clinical, P1 data, Journal: Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients. (Pubmed Central) - Oct 3, 2020
Supported by Mersana Therapeutics LIFA exhibited dose-proportional pharmacokinetics and an acceptable safety profile, with encouraging activity in PROC patients at the single-agent RP2D of 2.4 mg/kg.
- || Avastin (bevacizumab) / Roche, lifastuzumab vedotin (DNIB0600A) / Roche
Clinical, P1 data, Journal: Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. (Pubmed Central) - Jun 16, 2020
LIFA exhibited dose-proportional pharmacokinetics and an acceptable safety profile, with encouraging activity in PROC patients at the single-agent RP2D of 2.4 mg/kg. LIFA in combination with carboplatin ± bevacizumab demonstrated acceptable safety and encouraging activity in PSOC patients.
- || lifastuzumab vedotin (DNIB0600A) / Roche
Clinical, P2 data, Journal: Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. (Pubmed Central) - Nov 28, 2019
P2
While the response rate for the MMAE-containing ADC was promising, response durations were relatively short, thereby highlighting the importance of evaluating both response rates and duration of response when evaluating ADC's in OC. NCT01991210.
- | Avastin (bevacizumab) / Roche, lifastuzumab vedotin (DNIB0600A) / Roche
Trial completion, Enrollment change, Combination therapy: A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 4, 2017
P1, N=41, Completed, Sponsor: Genentech, Inc.
NCT01991210. Active, not recruiting --> Completed | N=33 --> 41
- | lifastuzumab vedotin (DNIB0600A) / Roche
Trial termination: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Aug 21, 2017
P2, N=95, Terminated, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | N=33 --> 41 Completed --> Terminated; The primary objective of PFS did not meet pre-specified criteria.
- |||| lifastuzumab vedotin (DNIB0600A) / Roche
Trial completion, Trial primary completion date: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Feb 17, 2017
P2, N=95, Completed, Sponsor: Genentech, Inc.
Completed --> Terminated; The primary objective of PFS did not meet pre-specified criteria. Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Aug 2016
- Avastin (bevacizumab) / Roche, lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 15, 2016
P1, N=33, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Aug 2016 Recruiting --> Active, not recruiting | N=42 --> 33 | Trial primary completion date: Sep 2015 --> Dec 2016
- ||| lifastuzumab vedotin (DNIB0600A) / Roche
Trial completion, Trial primary completion date: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Sep 2, 2016
P1, N=87, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | N=42 --> 33 | Trial primary completion date: Sep 2015 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> May 2016
- || lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment closed, Trial primary completion date: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Aug 8, 2016
P1, N=87, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> May 2016 Trial primary completion date: Mar 2017 --> Sep 2016 | Recruiting --> Active, not recruiting
- ||| lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment open: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Jul 5, 2016
P1, N=96, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Mar 2017 --> Sep 2016 | Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- || lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment closed: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - May 5, 2016
P1, N=87, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment closed: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Mar 7, 2015
P2, N=95, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- lifastuzumab vedotin (DNIB0600A) / Roche
Trial primary completion date: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Nov 20, 2014
P1, N=96, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> May 2016
- Avastin (bevacizumab) / Roche, lifastuzumab vedotin (DNIB0600A) / Roche
Trial completion date, Combination therapy: A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - May 11, 2014
P1, N=42, Recruiting, Sponsor: Genentech
Trial primary completion date: Feb 2016 --> May 2016 Trial completion date: Aug 2016 --> Jun 2016
- || lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment change: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Mar 30, 2014
P1, N=96, Recruiting, Sponsor: Genentech
Trial completion date: Aug 2016 --> Jun 2016 N=76 --> 96
- ||| lifastuzumab vedotin (DNIB0600A) / Roche
Trial initiation date: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Feb 23, 2014
P2, N=92, Recruiting, Sponsor: Genentech
N=76 --> 96 Initiation date: Nov 2013 --> Feb 2014
- | Avastin (bevacizumab) / Roche, lifastuzumab vedotin (DNIB0600A) / Roche
New P1 trial, Combination therapy: A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 24, 2013
P1, N=42, Recruiting, Sponsor: Genentech
- ||||| lifastuzumab vedotin (DNIB0600A) / Roche
New P2 trial: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Nov 21, 2013
P2, N=92, Recruiting, Sponsor: Genentech
- ||| lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment open: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Oct 16, 2011
P1, N=96, Recruiting, Sponsor: Genentech
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting